The FDA’s Interim Peptide Policy Isn’t Coming for RUO Stores
If your inbox filled up with “peptides are about to be legal” headlines this month, take a breath. The FDA interim peptide policy is real news, but it was written for compounding pharmacies. Not for research-use-only stores.
We build WooCommerce stores for peptide brands, and the question this news raises is simple: can you relax your product pages now? Short answer: no. Here’s why, and what you should do instead.
What actually happened
On October 15, 2026, HHS and FDA sent an “interim access policy” for certain peptides to the White House for review (AmSpa). It has not been published yet.
Based on reporting so far, it would let qualifying compounding pharmacies temporarily make some popular peptides, with BPC-157 named. FDA would do this through enforcement discretion, which means choosing not to act against those pharmacies. It is not an approval, and it is not a formal change to the 503A bulks list.
A few days later, HHS Secretary Robert F. Kennedy Jr. said on Fox News that the goal is a regulated, inspected peptide market, adding that “Americans are going to be buying these anyway” (GV Wire / Reuters).
Who the policy covers, and who it doesn’t
Holland & Knight expects any interim policy to cover 503A compounding pharmacies only. In its view, it would not reach research-use-only sellers, supplement brands or 503B outsourcing facilities (Holland & Knight).
The same alert points out that enforcement discretion can be withdrawn without formal rulemaking. So even the pharmacy lane is temporary until real rules arrive.
For the wider picture, see our guide to whether peptides are legal in the US in 2026. For an RUO store, nothing about your legal position changes. Your products are still unapproved drugs in FDA’s eyes if your site suggests human use.
The timeline so far
- April 15, 2026: FDA removed 12 peptides from Category 2, its list of substances with significant safety concerns.
- July 23–24, 2026: An FDA advisory committee voted to recommend six peptides for the compounding bulks list: BPC-157, KPV, TB-500, MOTS-c, Epitalon and Semax. The vote is advisory only.
- August 24, 2026: FDA sent five warning letters to online peptide vendors.
- October 15, 2026: The interim policy went to the White House.
- Before end of February 2027: A second advisory meeting is expected on GHK-Cu, LL-37, Dihexa, Melanotan II and PEG-MGF.
Notice that the warning letters landed in the middle of the “loosening” story. Both things are happening at once.
Update, October 30: HHS has now published the final policy. We break down what it means for stores in HHS peptide compounding policy: what it means for peptide stores.
What this means for your store
Don’t add “now legal” or “FDA-cleared” language. Nothing has been cleared. A single banner like that can turn a research catalog into a human-use marketing site overnight.
Don’t launch SKUs or campaigns that depend on the policy. If BPC-157 ends up compoundable, it will be compoundable by pharmacies with prescriptions. Not by your checkout.
Keep your compliance copy and checkout attestations exactly where they are. Underwriters read the news too. Expect them to ask harder questions, not easier ones.
Start mapping a second lane if human use is your real market. The money is moving toward pharmacies and telehealth. Leerink Partners estimated a $2.2 billion annual telehealth peptide market if all seven reviewed peptides open up (Stocktwits). That’s a different business with a different site, and it pays to plan it before the rule text drops.
How we handle this for clients
When we built Arcane Peptides, the client wanted tighter control over who sees what. We set up the store so some products are hidden from logged-out visitors, and buying requires an account. That kind of gating is exactly what makes a later split into an RUO store and a prescription storefront easier. It also took around 100 hours, which is fast for a store of that size.
If you’re not sure how your product pages read to a regulator, start with our peptide store compliance website audit guide. If you want the store rebuilt with the right structure from day one, that’s our peptide store design and development service.
The bottom line
The interim policy is a pharmacy story. For RUO stores, the safest move this quarter is boring: keep copy research-framed, keep checkout attestations tight, and plan any human-use channel as a separate, compliant business.
We’ll update this post when the policy text is published.
Ready to check your store before the rules land? Book a free peptide store call.
This article is for information only and is not legal advice. Talk to a regulatory attorney about your specific products.
Sources: AmSpa · Holland & Knight · GV Wire / Reuters · Stocktwits · Orrick


